Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.
You may also be interested in...
GSK Highlights R&D Productivity Gains In First Quarter
Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.
GSK Highlights R&D Productivity Gains In First Quarter
Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.
GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010
GlaxoSmithKline plans to divest non-core OTC brands this year as CEO describes 2010 as a challenging year.